Imugene Limited

ASX (AUD): Imugene Limited (IMU)

Last Price

0.057

Today's Change

+0.001 (1.78%)

Day's Change

0.054 - 0.057

Trading Volume

8,347,991

Overview

Market Cap

418 Million

Shares Outstanding

7 Billion

Avg Volume

21,349,932

Avg Price (50 Days)

0.06

Avg Price (200 Days)

0.09

PE Ratio

-5.70

EPS

-0.01

Earnings Announcement

23-Aug-2024

Previous Close

0.06

Open

0.06

Day's Range

0.054 - 0.057

Year Range

0.039 - 0.15

Trading Volume

8,347,991

Price Change Highlight

1 Day Change

1.79%

5 Day Change

-5.00%

1 Month Change

-3.39%

3 Month Change

-19.72%

6 Month Change

-45.71%

Ytd Change

-48.18%

1 Year Change

-39.36%

3 Year Change

-83.24%

5 Year Change

200.00%

10 Year Change

310.84%

Max Change

-99.60%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment